Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M86,627Revenue $M18,790Net Margin (%)22.0Z-Score4.0
Enterprise Value $M91,918EPS $2.6Operating Margin %30.1F-Score6
P/E(ttm))21.1Cash Flow Per Share $0Pre-tax Margin (%)28.4Higher ROA y-yN
Price/Book18.310-y EBITDA Growth Rate %0Quick Ratio2.6Cash flow > EarningsY
Price/Sales4.65-y EBITDA Growth Rate %0Current Ratio2.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-10.5ROA % (ttm)14.1Higher Current Ratio y-yY
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)91.9Less Shares Outstanding y-yN
Payout Ratio %62.0Shares Outstanding M1,590ROI % (ttm)22.2Gross Margin Increase y-yY

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVJoel Greenblatt 2014-03-31 Add0.1%$46.83 - $53.68
($50.6)
$ 54.488%Add 120.38%229,149
ABBVGeorge Soros 2014-03-31 Reduce-0.35%$46.83 - $53.68
($50.6)
$ 54.488%Reduce -69.5%350,000
ABBVVanguard Health Care Fund 2014-03-31 Sold Out -0.28%$46.83 - $53.68
($50.59)
$ 54.488%Sold Out0
ABBVDavid Dreman 2014-03-31 Sold Out -0.02%$46.83 - $53.68
($50.6)
$ 54.488%Sold Out0
ABBVDavid Dreman 2013-12-31 Buy 0.02%$44.52 - $54.32
($49.14)
$ 54.4811%New holding, 4572 sh.4,572
ABBVVanguard Health Care Fund 2013-12-31 Reduce-1.03%$44.52 - $54.32
($49.14)
$ 54.4811%Reduce -79.44%1,739,600
ABBVJohn Hussman 2013-12-31 Reduce-0.25%$44.52 - $54.32
($49.14)
$ 54.4811%Reduce -24.8%303,250
ABBVJoel Greenblatt 2013-12-31 Reduce-0.06%$44.52 - $54.32
($49.14)
$ 54.4811%Reduce -26.75%103,981
ABBVJoel Greenblatt 2013-09-30 Add0.06%$42.21 - $47.92
($44.37)
$ 54.4823%Add 39.51%141,954
ABBVGeorge Soros 2013-06-30 Add0.3%$40.57 - $47.17
($43.74)
$ 54.4825%Add 203.98%1,008,752
ABBVJoel Greenblatt 2013-06-30 Add0.11%$40.57 - $47.17
($43.74)
$ 54.4825%Add 171.43%101,753
ABBVMario Gabelli 2013-06-30 Reduce$40.57 - $47.17
($43.74)
$ 54.4825%Reduce -36.12%10,080
ABBVDaniel Loeb 2013-06-30 Sold Out -2.3%$40.57 - $47.17
($43.74)
$ 54.4825%Sold Out0
ABBVVanguard Health Care Fund 2013-06-30 Reduce-0.93%$40.57 - $47.17
($43.74)
$ 54.4825%Reduce -40.22%8,459,700
ABBVVanguard Health Care Fund 2013-03-31 Add2.03%$33.71 - $40.78
($36.98)
$ 54.4847%Add 760.24%14,151,000
ABBVDaniel Loeb 2013-03-31 Add1.98%$33.71 - $40.78
($36.98)
$ 54.4847%Add 609.13%2,950,000
ABBVJohn Hussman 2013-03-31 Buy 0.6%$33.71 - $40.78
($36.98)
$ 54.4847%New holding, 403250 sh.403,250
ABBVPRIMECAP Management 2013-03-31 Buy 0.36%$33.71 - $40.78
($36.98)
$ 54.4847%New holding, 5991647 sh.5,991,647
ABBVGeorge Soros 2013-03-31 Buy 0.16%$33.71 - $40.78
($36.98)
$ 54.4847%New holding, 331852 sh.331,852
ABBVJoel Greenblatt 2013-03-31 Buy 0.08%$33.71 - $40.78
($36.98)
$ 54.4847%New holding, 37488 sh.37,488
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ABBV Joel Greenblatt 2014-03-31229,1490.010.18+120.38%
ABBV PRIMECAP Management 2014-03-316,335,7220.40.37+8.29%
ABBV Mario Gabelli 2014-03-3110,46200+3.79%
ABBV Dodge & Cox 2014-03-3136,70100+0.14%
ABBV John Hussman 2014-03-31303,2500.021.2
ABBV George Soros 2014-03-31350,0000.020.18-69.5%
ABBV Vanguard Health Care Fund 2014-03-31000Sold Out
ABBV David Dreman 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GONZALEZ RICHARD AChairman of the Board and CEO 2014-03-04Sell4,799$51.25.57view
ALBAN CARLOSEVP, Commercial Operations 2014-03-03Sell2,882$50.097.91view
CHASE WILLIAM JEVP, CFO 2014-03-03Sell3,948$50.227.63view
SALEKI-GERHARDT AZITASVP, Operations 2014-03-03Sell2,443$50.257.56view
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC 2014-03-03Sell4,143$50.038.04view
RICHMOND TIMOTHY J.SVP, Human Resources 2014-02-18Sell465$51.235.5view
RICHMOND TIMOTHY J.SVP, Human Resources 2014-02-05Sell1,460$47.7813.12view
SALEKI-GERHARDT AZITASVP, Operations 2014-02-05Sell687$47.8412.98view
SALEKI-GERHARDT AZITASVP, Operations 2013-09-17Sell10,473$45.8417.91view
SALEKI-GERHARDT AZITASVP, Operations 2013-08-19Sell1,270$43.0125.67view

Press Releases about ABBV :

    Quarterly/Annual Reports about ABBV:

    News about ABBV:

    Articles On GuruFocus.com
    Why AbbVie Looks Like a Sell Jul 18 2014 
    Why Gilead Sciences Will Grow to $100 Jul 18 2014 
    Why I Bought Baxter International Jun 19 2014 
    The Top 5 Guru-Held Spin-Offs Jun 06 2014 
    Competition From AbbVie Will Not Hurt Gilead Sciences Apr 27 2014 
    Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 21 2014 
    Lountzis Asset Management Comments on Abbvie Mar 21 2014 
    Companies That Increased Dividends Lately Feb 24 2014 
    8 Big-Name Stocks Raising Dividends and Expectations Feb 24 2014 
    We Were Dividends, Before Dividends Were Cool Jan 29 2014 

    More From Our Partners
    Johnson & Johnson Announces $5B Share Buyback - Analyst Blog Jul 22 2014 - ZACKS
    FT: 25 More Firms May Seek Tax Breaks Overseas Jul 22 2014 - FOXBUSINESS

    More From Other Websites
    Shire to spend about $225M on drug collaboration Jul 23 2014
    Rule 2.10 Announcement Jul 23 2014
    Dividend Growth Investing: An Open Portfolio For Your Review Jul 22 2014
    [video] Don't Expect Tax Inversion Fever to Break Anytime Soon Jul 22 2014
    Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014
    Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014
    Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014
    Shire's Q2 Earnings Strong but Overshadowed by AbbVie Deal Jul 22 2014
    U.S. Senate panel to debate wave of corporate tax-avoidance deals Jul 22 2014
    Rule 2.10 Announcement Jul 22 2014
    U.S. Senate panel to debate wave of corporate tax-avoidance deals Jul 22 2014
    U.S. Senate panel to debate wave of corporate tax-avoidance deals Jul 21 2014
    U.S. Senate panel to debate wave of corporate tax-avoidance deals Jul 21 2014
    Abbvie's $8 billion in tax breaks from Shire deal may come just in time Jul 21 2014
    AbbVie Set to Acquire UK-Based Shire in Q4 Jul 21 2014
    ABBV, MRK And PFE, Pushing Health Care Sector Downward Jul 21 2014
    Tax inversions allow firms to avoid state taxes Jul 21 2014
    [video] Mega drug merger Jul 21 2014
    Hepatitis C Spurs Unusual Patent Wars Among Big Drug Makers Jul 21 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide